Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

被引：0
|
作者：
Ding, Qian [1 ]
Guan, Ming-Cheng [1 ]
Zhu, Hong [1 ,2 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[2] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, 899,Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2023年 / 192卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.ejca.2023.113263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
    Persano, Mara
    Rimini, Margherita
    Gardini, Andrea Casadei
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [2] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
    Persano, Mara
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Tovoli, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Niizeki, Takashi
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Stefanini, Bernardo
    Hiraoka, Atsushi
    Sho, Takuya
    Nishida, Naoshi
    Steup, Christoph
    Iavarone, Massimo
    Di Costanzo, Giovanni
    Marra, Fabio
    Tamburini, Emiliano
    Cabibbo, Giuseppe
    Foschi, Francesco Giuseppe
    Silletta, Marianna
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    EUROPEAN JOURNAL OF CANCER, 2023, 189
  • [3] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
    Persano, M.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Piscaglia, F.
    Iavarone, M. A.
    Tamburini, E.
    Cabibbo, G.
    Silletta, M.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S603 - S604
  • [4] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
    Persano, Mara
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shigeo, Shimose
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Piscaglia, Fabio
    Iavarone, Massimo
    Di Costanzo, Giuseppe
    Marra, Fabio
    Cabibbo, Giuseppe
    Foschi, Francesco
    Siletta, Marianna
    Cascinu, Stefano
    Scartozzi, Mario
    Gardini, Andrea Casadei
    JOURNAL OF HEPATOLOGY, 2023, 78 : S593 - S594
  • [5] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
    Persano, M.
    Rimini, M.
    Toshifumi, T.
    Suda, G.
    Shigeo, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Tovoli, F.
    Piscaglia, F.
    Iavarone, M.
    Marra, F.
    Tamburini, E.
    Cabibbo, G.
    Scartozzi, M.
    Casadei-Gardini, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S6 - S7
  • [6] Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
    Chen, Yen-Hao
    Chen, Yen-Yang
    Wang, Jing-Houng
    Hung, Chao-Hung
    ANTICANCER RESEARCH, 2023, 43 (03) : 1377 - 1384
  • [7] Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.
    Yang, JIwon
    Choi, Won-Mook
    Kim, Hyung-Don
    Choi, Jonggi
    Yoo, Changhoon
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 558 - 558
  • [8] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
  • [9] Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
    Yang, Jiwon
    Choi, Won-Mook
    Kim, Hyung-Don
    Choi, Jonggi
    Yoo, Changhoon
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    LIVER CANCER, 2024,
  • [10] The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib
    Chihiro, Kikukawa
    Kawaoka, Tomokazu
    Uchikawa, Shinsuke
    Kinami, Takahiro
    Yamasaki, Shintaro
    Kosaka, Masanari
    Johira, Yusuke
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Yamaoka, Kenji
    Teraoka, Yuji
    Uchida, Takuro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Miki, Daiki
    Tsuge, Masataka
    Imamura, Michio
    Aikata, Hiroshi
    Oka, Shiro
    ONCOLOGY, 2023, 101 (08) : 491 - 501
12345